Obesity News

SAN ANTONIO — The disruptive SELECT trial not only bolstered the idea of medical obesity therapy as an avenue for heart disease prevention, its subanalyses continue to generate interesting new hypotheses, speakers reported.

SAN ANTONIO — Patient interviews showed weight loss via GLP-1 receptor agonists is a major emotional journey, many have anxiety surrounding cessation and weight regain due to lack of access, a speaker reported.

SAN ANTONIO — Dysregulated amino and fatty acid metabolism during late pregnancy was tied to elevated incidence of type 2 diabetes among women with a history of gestational diabetes, according to a presentation at ObesityWeek.

SAN ANTONIO — At 24 months, children who received a health literacy-informed digital text and web-based intervention had better weight trajectories vs. those who did not, according to Greenlight Plus Trial results presented at ObesityWeek.

After decades of research, pharmacologic treatment of obesity gained significant traction with the launch of GLP-1 receptor agonists, and several potentially more potent drugs are currently in the pipeline, a speaker reported.

A decade after receiving gastric bypass or sleeve gastrectomy as adolescents, many people maintain their weight loss and achieve remission of obesity-related conditions, including diabetes, according to a study.

BOSTON — Behavioral modification with diet and exercise demonstrated similar weight-loss benefits vs. other pharmaceutical and surgical approaches to obesity management, but patients must remain adherent, a speaker reported.

PHILADELPHIA — Although glucagon-like peptide-1 receptor agonist use may increase the risk for retained gastric contents in those undergoing endoscopic procedures, a 24-hour clear liquid diet may be “protective” vs. holding the medication.

Products claiming to work like GLP-1s are popular and misleading, but primary care providers can help their patients avoid potentially dangerous supplements, according to experts.

PHILADELPHIA — None of the top 25 insurers in the United States offer explicit policy coverage for primary or revisional endoscopic bariatric therapies, according to data presented at the ACG Annual Scientific Meeting.